Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid–binding protein in necrotizing enterocolitis

Reisinger, Kostan W.; Zee, David C. van der; Brouwers, H. A. A.; Kramer, Boris W.; Heurn, L. W. Ernest van; Buurman, Wim A.; Derikx, Joep P. M.

doi:10.1016/j.jpedsurg.2012.02.027

Cited by 60 publications

(52 citation statements)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This gives the clinician the opportunity to select the best possible way to measure I-FABP. Although several studies report on I-FABP measured in plasma [3,4,19] and serum [20], and several others on the use of urinary I-FABP measurements [5,12,13,14], no literature compares both methods. Several positive and negative aspects of both measuring methods can be identified.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intestinal Fatty Acid-Binding Protein in Neonates with Imminent Necrotizing Enterocolitis

Schurink¹,

Scholten²,

Kooi

et al. 2014

Neonatology

View full text Add to dashboard Cite

Background: Intestinal fatty acid-binding protein (I-FABP) is a promising marker for necrotizing enterocolitis (NEC). It can be measured in plasma (I-FABPp) and urine (I-FABPu). Data on the best way to measure I-FABP (in plasma or urine) and the necessity of simultaneous measurement of the urinary creatinine concentration to correct for physiological variations in urine concentration are not available. This holds also true for the reciprocal relation between I-FABPp, I-FABPu and other more conventional laboratory parameters. Objectives: To evaluate the above-mentioned correlations of I-FABP measurements in neonates with suspected NEC. Methods: All neonates with suspected NEC were prospectively included. I-FABPp and I-FABPu were analyzed at regular intervals during the first 24 h after onset of symptoms. Correlation and agreement were assessed between these and other parameters (i.e. IL-6, WBC, platelet count, CRP, pH and lactate). Results: Included were 24 boys, 13 girls [median (range) GA 28 weeks (24-36), median birth weight 1,190 g (570-2,400)]. I-FABPu correlated strongly with I-FABPp (r 0.80, p < 0.001) with an adequate agreement. A very strong correlation between I-FABPu and I-FABPu/urine creatinine ratio (r 0.98, p < 0.001) existed. Correlations between I-FABPp/u and conventional parameters were moderate to strong until 8 h after onset of symptoms. Conclusion: In neonates with suspected NEC, I-FABPu correlates strongly with I-FABPp, offering an opportunity to choose the most appropriate way of measuring I-FABP. Calculating urinary IFABP/creatinine ratio seems redundant. Moderately strong correlations between I-FABPu and IL-6, WBC and lactate were found.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is considered customary by some to determine the ratio between I-FABPu and urine creatinine to compensate for physiological variations in urine concentration, but no data are available on the necessity of determining this ratio [5,12,13,14]. …”

Section: Introductionmentioning

confidence: 99%

Intestinal Fatty Acid-Binding Protein in Neonates with Imminent Necrotizing Enterocolitis

Schurink¹,

Scholten²,

Kooi

et al. 2014

Neonatology

View full text Add to dashboard Cite

show abstract

“…68,69 Recently, a combination of urinary I-FABP and FC provided a sensitivity of 94%, a specificity of 79%, a positive likelihood ratio of 4.48, and a negative likelihood ratio of 0.08, for diagnosing NEC in a cohort of neonates. 70 In that case, those investigators looked to improve I-FABP's ability to diagnose NEC by adding FC assessment, as I-FABP alone had not been definitive in previous analyses of their cohort. 71 FC was also analyzed to establish a possible relationship between gut inflammation and linear growth in 144 urban and rural Chinese infants.…”

Section: In Other Gi Diseasesmentioning

confidence: 99%

Calprotectin: Clinical Applications in Pediatrics

Herrera

Christensen

Helms

2016

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

As seen over the past 20 years, calprotectin has evolved as a novel, non-invasive biomarker of gastrointestinal (GI) inflammation. We present this review of calprotectin in pediatrics. This article will focus on studies using calprotectin concentrations from different body fluids to monitor inflammation in different disease states and conditions. The ultimate goal of our group is to lay down a foundation as we consider using calprotectin prospectively as a marker of intestinal inflammation that could lead to further testing and possibly a marker of preparedness for feeding. We surveyed all published studies in English of calprotectin in neonates, infants, children, and adolescents through February 2014. We will discuss calprotectin's basic properties and analysis such as characteristics, identification, presence in body fluids, and maturational development. In addition, calprotectin's use in inflammatory diseases exploring both GI and non-GI conditions will be evaluated and compared with other serum markers presently available. Finally, a summary of our findings and discussion of future work that could be undertaken in order to render calprotectin as a more useful monitoring tool to the medical research community will complete the review.

show abstract

“…Intestinal barrier function can be assessed by urinary measurement of Biomarkers such as intestinal fatty acid-binding protein (I-FABP) and fecal measurement of calprotectin [39,40] and optimising intestinal barrier function may be important in preventing NEC [41]. Altered microbial colonization: 'Microbiota' can be defined as the microbes associated with a particular context.…”

Section: Nec Sipmentioning

confidence: 99%

Necrotizing Enterocolitis (NEC): A Devastating Disease of Prematurity

Garg¹,

Garg²,

Lal³

2015

J Neonatal Biol

View full text Add to dashboard Cite

Necrotizing Enterocolitis (NEC) is a common and devastating gastrointestinal emergency that primarily affects premature infants. The incidence of necrotizing enterocolitis is 6-10% among infants with birth weight less than 1500 grams. The mortality due to NEC has not improved significantly despite advances in neonatal care and better understanding of clinical and basic sciences. The pathogenesis of NEC is not well understood and several factors such as prematurity, abnormal colonization with pathogenic bacteria, feeding practices, blood transfusion and altered intestinal barrier function may be involved. The clinical presentation of NEC could be sudden and the treatment plan could vary with the stage and type of presentation. Further research is needed to better understand the pathophysiology of NEC and, biomarkers for prediction, prevention and treatment need to be developed. Further clinical trials are needed to determine prevention and treatment modalities for this devastating disease.

show abstract

Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid–binding protein in necrotizing enterocolitis

Cited by 60 publications

References 22 publications

Intestinal Fatty Acid-Binding Protein in Neonates with Imminent Necrotizing Enterocolitis

Intestinal Fatty Acid-Binding Protein in Neonates with Imminent Necrotizing Enterocolitis

Calprotectin: Clinical Applications in Pediatrics

Necrotizing Enterocolitis (NEC): A Devastating Disease of Prematurity

Contact Info

Product

Resources

About